The efficacy of a polyhydrated ionogen impregnated dressing in the treatment of recalcitrant diabetic foot ulcers: a multi-centre pilot study.
OBJECTIVE
Assessing the efficacy of a polyhydrated ionogen impregnated dressing in the treatment of recalcitrant diabetic foot ulcers.


BACKGROUND
Diabetic Foot Ulcers (DFU) continue to present a formidable challenge in terms of morbidity and health care costs. Increasing evidence ascertains the important role of Matrix MetalloProteinases (MMPs) and their tissue inhibitors, TIMPs, in wound healing. Imbalance of MMPs in the DFU microenvironment has been associated with poor wound healing. Current research is directed towards therapeutic agents that could redress the imbalance of MMPs/TIMPs. Poly Hydrated Ionogen (PHI) formulation is based on metallic ions and citric acid. PHI application aims to positively restore MMP ratios within chronic wounds. This initial multi-centre pilot study aimed to investigate the efficacy of the PHI formulation in achieving stable wound closure in recalcitrant DFUs.


METHODS
Twenty patients with therapy resistant DFUs of at least 1 cm2 and 3 months duration were treated with PHI formulation in an acetate carrier dressing. Wound debridement, digital imaging and wound perimeter tracing was performed weekly. Off-loading was performed by the use of appropriate shoe-wear (cut-out sandals) and crutches. Patient satisfaction was assessed with a questionnaire. A detailed evaluation sheet was kept for every patient and updated at each visit.


RESULTS
Stable wound closure with high patient satisfaction was achieved in 16 (80%) DFUs. The mean time to full closure was 18 weeks. A stable wound epithelization was seen in all full closure patients up to latest follow-up of one year.


CONCLUSIONS
Encouraging results of this pilot study prompt us to further investigate the PHI efficacy in DFU treatment in a multi-centre, randomized controlled trial.
Pirayesh
A
A
Department of Plastic, Reconstructive and Aesthetic Surgery, University Hospital, Ghent, Belgium. apirayesh@doctors.org.uk
Dessy
L A
LA
Rogge
F J
FJ
Hoeksema
H J P
HJ
Sinove
Y M G
YM
Dall' Antonia
A
A
Jawad
M A
MA
Gilbert
P M
PM
Rubino
C
C
Scuderi
N
N
Blondeel
R
R
Monstrey
S
S
D000328:Adult; D000368:Aged; D017719:Diabetic Foot / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012413:Rubidium / Q000627:therapeutic use*; D016896:Treatment Outcome; D014945:Wound Healing; D015032:Zinc / Q000627:therapeutic use*
C523779:PHI-5 formulation; D015032:Zinc; D012413:Rubidium